APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.

Bibliographic Details
Main Authors:	Croucher, P, Shipman, C, Perry, M, Russell, G, Van Camp, B, Niesor, E, Bentzen, C, Vanderkerken, K
Format:	Conference item
Published:	2002

Similar Items

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
by: Edwards, C, et al.
Published: (2007)

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2005)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2006)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
by: Roelofs, A, et al.
Published: (2007)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
by: Staci L. Haney, et al.
Published: (2022-12-01)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
by: Mueller, G, et al.
Published: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
by: Mueller, G, et al.
Published: (2004)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
by: De Leenheer, E, et al.
Published: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
by: Locklin, R, et al.
Published: (2007)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
by: Clive Henry Buckle, et al.
Published: (2012-01-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
by: Croucher, P, et al.
Published: (2003)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
by: Roelofs, A, et al.
Published: (2004)

Histone deacetylase inhibitors in multiple myeloma
by: Sarah Deleu, et al.
Published: (2009-06-01)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
by: Locklin, R, et al.
Published: (2007)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
by: Shipman, C, et al.
Published: (2000)

Advances in the management of myeloma bone disease.
by: Shipman, C, et al.
Published: (2005)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
by: Gordon, S, et al.
Published: (1999)

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
by: Roelofs, A, et al.
Published: (2006)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)